COSCIENS BIOPHARMA INC (CSCI.CA) Fundamental Analysis & Valuation

TSX:CSCI • CA22112H1010

Current stock price

1.11 CAD
+0.01 (+0.91%)
Last:

This CSCI.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. CSCI.CA Profitability Analysis

1.1 Basic Checks

  • CSCI had negative earnings in the past year.
  • In the past year CSCI has reported a negative cash flow from operations.
  • In the past 5 years CSCI always reported negative net income.
  • CSCI had a negative operating cash flow in each of the past 5 years.
CSCI.CA Yearly Net Income VS EBIT VS OCF VS FCFCSCI.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M

1.2 Ratios

  • The Return On Assets of CSCI (-62.48%) is better than 60.87% of its industry peers.
  • CSCI's Return On Equity of -293.43% is fine compared to the rest of the industry. CSCI outperforms 60.87% of its industry peers.
Industry RankSector Rank
ROA -62.48%
ROE -293.43%
ROIC N/A
ROA(3y)-32.96%
ROA(5y)-24.63%
ROE(3y)-65.43%
ROE(5y)-50.16%
ROIC(3y)N/A
ROIC(5y)N/A
CSCI.CA Yearly ROA, ROE, ROICCSCI.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 -400

1.3 Margins

  • The Gross Margin of CSCI (45.14%) is better than 73.91% of its industry peers.
  • In the last couple of years the Gross Margin of CSCI has grown nicely.
  • CSCI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 45.14%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.48%
GM growth 5Y19.79%
CSCI.CA Yearly Profit, Operating, Gross MarginsCSCI.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. CSCI.CA Health Analysis

2.1 Basic Checks

  • CSCI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for CSCI has been increased compared to 1 year ago.
  • The number of shares outstanding for CSCI has been increased compared to 5 years ago.
  • The debt/assets ratio for CSCI has been reduced compared to a year ago.
CSCI.CA Yearly Shares OutstandingCSCI.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
CSCI.CA Yearly Total Debt VS Total AssetsCSCI.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

  • CSCI has an Altman-Z score of -1.76. This is a bad value and indicates that CSCI is not financially healthy and even has some risk of bankruptcy.
  • CSCI's Altman-Z score of -1.76 is fine compared to the rest of the industry. CSCI outperforms 69.57% of its industry peers.
  • CSCI has a Debt/Equity ratio of 0.39. This is a healthy value indicating a solid balance between debt and equity.
  • CSCI's Debt to Equity ratio of 0.39 is fine compared to the rest of the industry. CSCI outperforms 60.87% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.39
Debt/FCF N/A
Altman-Z -1.76
ROIC/WACCN/A
WACC7.27%
CSCI.CA Yearly LT Debt VS Equity VS FCFCSCI.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

  • A Current Ratio of 3.47 indicates that CSCI has no problem at all paying its short term obligations.
  • With an excellent Current ratio value of 3.47, CSCI belongs to the best of the industry, outperforming 82.61% of the companies in the same industry.
  • CSCI has a Quick Ratio of 3.03. This indicates that CSCI is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Quick ratio value of 3.03, CSCI is doing good in the industry, outperforming 78.26% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.47
Quick Ratio 3.03
CSCI.CA Yearly Current Assets VS Current LiabilitesCSCI.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. CSCI.CA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 39.32% over the past year.
  • CSCI shows a strong growth in Revenue. In the last year, the Revenue has grown by 41.78%.
  • The Revenue has been growing by 80.53% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)39.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.1%
Revenue 1Y (TTM)41.78%
Revenue growth 3Y21.84%
Revenue growth 5Y80.53%
Sales Q2Q%-20.74%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CSCI.CA Yearly Revenue VS EstimatesCSCI.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
CSCI.CA Yearly EPS VS EstimatesCSCI.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2021 2022 2023 2024 0 -50 -100 -150 -200

More info and screens

Find the best growth stocksShow best growing peers

0

4. CSCI.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CSCI. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CSCI.CA Price Earnings VS Forward Price EarningsCSCI.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CSCI.CA Per share dataCSCI.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CSCI.CA Dividend Analysis

5.1 Amount

  • No dividends for CSCI!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CSCI.CA Fundamentals: All Metrics, Ratios and Statistics

COSCIENS BIOPHARMA INC

TSX:CSCI (3/20/2026, 7:00:00 PM)

1.11

+0.01 (+0.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-11
Earnings (Next)04-15
Inst Owners8.08%
Inst Owner ChangeN/A
Ins Owners0.13%
Ins Owner ChangeN/A
Market Cap3.53M
Revenue(TTM)9.05M
Net Income(TTM)-14.91M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.28
P/FCF N/A
P/OCF N/A
P/B 0.51
P/tB 0.51
EV/EBITDA N/A
EPS(TTM)-6.49
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-4.73
FCFYN/A
OCF(TTM)-4.31
OCFYN/A
SpS3.91
BVpS2.19
TBVpS2.19
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -62.48%
ROE -293.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 45.14%
FCFM N/A
ROA(3y)-32.96%
ROA(5y)-24.63%
ROE(3y)-65.43%
ROE(5y)-50.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.48%
GM growth 5Y19.79%
F-Score5
Asset Turnover0.38
Health
Industry RankSector Rank
Debt/Equity 0.39
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 75.06%
Cap/Sales 10.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.47
Quick Ratio 3.03
Altman-Z -1.76
F-Score5
WACC7.27%
ROIC/WACCN/A
Cap/Depr(3y)43.14%
Cap/Depr(5y)N/A
Cap/Sales(3y)7.47%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)39.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.1%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)41.78%
Revenue growth 3Y21.84%
Revenue growth 5Y80.53%
Sales Q2Q%-20.74%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y31.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y27.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.02%
OCF growth 3YN/A
OCF growth 5YN/A

COSCIENS BIOPHARMA INC / CSCI.CA Fundamental Analysis FAQ

What is the fundamental rating for CSCI stock?

ChartMill assigns a fundamental rating of 3 / 10 to CSCI.CA.


What is the valuation status for CSCI stock?

ChartMill assigns a valuation rating of 0 / 10 to COSCIENS BIOPHARMA INC (CSCI.CA). This can be considered as Overvalued.


How profitable is COSCIENS BIOPHARMA INC (CSCI.CA) stock?

COSCIENS BIOPHARMA INC (CSCI.CA) has a profitability rating of 2 / 10.